Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH

被引:0
|
作者
Fabian Pitoia
Erika Abelleira
Graciela Cross
机构
[1] University of Buenos Aires,Division of Endocrinology–Hospital de Clínicas
来源
Endocrine | 2017年 / 55卷
关键词
Thyroglobulin levels; Remnant ablation; Differentiated thyroid cancer; Excellent response; Preparation mode; Risk of recurrence;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of our study was to evaluate the prognostic value of stimulated thyroglobulin levels at the moment of remnant ablation for predicting an initial excellent or a structural incomplete response to treatment according to the risk of recurrence in patients with differentiated thyroid cancer. Patients were divided into two groups according to the preparation mode for remnant ablation (thyroid hormone withdrawal or recombinant human TSH). We included 219 patients followed-up for at least for 24 months after remnant ablation. The primary endpoint was the best response to initial therapy assessed in the first 9–18 months of follow-up. An excellent response was observed in 45.1 % of patients prepared after recombinant human TSH compared to 44.6 % of patients prepared after thyroid hormone withdrawal (P = NS). The cutoff value of thyroglobulin level after recombinant human TSH for predicting an excellent response was 8 ng/ml (n = 51), with a sensitivity of 73.9 %, and a positive predictive value of 61 %. It was similar for patients with low vs. intermediate to high risk of recurrence. This cutoff value for thyroglobulin level after thyroid hormone withdrawal was 22 ng/ml (n = 168), with a sensitivity of 94.7 % and a positive predictive value of 61.7 %. In the thyroid hormone withdrawal group the thyroglobulin cutoff level was 12 ng/ml for low-risk patients compared to 16 ng/ml for those with intermediate to high risk of recurrence (P = 0.003). The cutoff value of the thyroglobulin level for predicting a structural incomplete response to initial treatment was 20 ng/ml after rhTSH, with a negative predictive value of 91.4 %. This level was higher in thyroid hormone withdrawal group, and it was established at 25 ng/ml, with a negative predictive value of 97.7 %. The stimulated Tg level seems to be different depending on the preparation mode (rhTSH or THW) for RA. It has a high NPV to predict the absence of a structural incomplete response and it is also a good predictor of the initial excellent response and the NED status at the end of follow-up.
引用
收藏
页码:200 / 208
页数:8
相关论文
共 50 条
  • [41] Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri, EL
    Kloos, RT
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (04): : 1490 - 1498
  • [42] Radioiodine thyroid remnant ablation (RRA) in patients with differentiated thyroid cancer (DTC): Impact of recombinant human thyroid-stimulating hormone (rhTSH) on treatment room length-of-stay and utilization
    Antonio Vallejo, Juan
    Mena, Luisa
    Angeles Galvez, Maria
    Marlowe, Robert
    Latre, Jose
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [43] Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management
    Chen, Ming-Kai
    Doddamane, Indukala
    Cheng, David W.
    CURRENT OPINION IN ONCOLOGY, 2010, 22 (01) : 6 - 10
  • [44] Response Prediction of Altered Thyroglobulin Levels After Radioactive Iodine Therapy Aided by Recombinant Human Thyrotropin in Patients with Differentiated Thyroid Cancer
    Song M.
    Jeon S.
    Kang S.-R.
    Jabin Z.
    Yoo S.W.
    Min J.-J.
    Bom H.-S.
    Cho S.-G.
    Kim J.
    Song H.-C.
    Kwon S.Y.
    Nuclear Medicine and Molecular Imaging, 2018, 52 (4) : 287 - 292
  • [45] Can serum thyroglobulin levels predict patient outcome after treatment of differentiated thyroid carcinoma?
    Steven I Sherman
    Nature Clinical Practice Endocrinology & Metabolism, 2007, 3 : 510 - 511
  • [46] Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone
    Berg, G
    Lindstedt, G
    Suurküla, M
    Jansson, S
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2002, 25 (01) : 44 - 52
  • [47] Iodine Biokinetics and Radioiodine Exposure after Recombinant Human Thyrotropin-Assisted Remnant Ablation in Comparison with Thyroid Hormone Withdrawal
    Taieb, D.
    Sebag, F.
    Farman-Ara, B.
    Portal, T.
    Baumstarck-Barrau, K.
    Fortanier, C.
    Bourrelly, M.
    Mancini, J.
    De Micco, C.
    Auquier, P.
    Conte-Devolx, B.
    Henry, J. F.
    Mundler, O.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (07): : 3283 - 3290
  • [48] Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone
    G. Berg
    G. Lindstedt
    M. Suurküla
    S. Jansson
    Journal of Endocrinological Investigation, 2002, 25 : 44 - 52
  • [49] A study of the time of hospital discharge of differentiated thyroid cancer patients after receiving iodine-131 for thyroid remnant ablation treatment
    Azizmohammadi, Zahra
    Tabei, Faraj
    Shafiei, Babak
    Babaei, Ali Akbar
    Jukandan, Seyed Mohsen Qutbi
    Naghshine, Reza
    Javadi, Hamid
    Nabipour, Iraj
    Assadi, Majid
    Asli, Isa Neshandar
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2013, 16 (02): : 103 - 106
  • [50] A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation
    Robbins, RJ
    Larson, SM
    Sinha, N
    Shaha, A
    Divgi, C
    Pentlow, KS
    Ghossein, R
    Tuttle, RM
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (11) : 1482 - 1488